Heron Therapeutics (HRTX) : The highest short term price target forecast on Heron Therapeutics (HRTX) is $55 and the lowest target price is $33. A total of 8 equity analysts are currently covering the company. The average price of all the analysts is $43.75 with a standard deviation of $7.01.
Heron Therapeutics (HRTX) : 8 brokerage houses believe that Heron Therapeutics (HRTX) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 8 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
Heron Therapeutics (NASDAQ:HRTX): The stock opened at $18.54 on Thursday but the bulls could not build on the opening and the stock topped out at $18.95 for the day. The stock traded down to $17.85 during the day, due to lack of any buying support eventually closed down at $18.33 with a loss of -1.45% for the day. The stock had closed at $18.60 on the previous day. The total traded volume was 594,199 shares.
Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Companys product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Companys product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Companys other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.